Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Acelyrin Inc (NQ: SLRN ) 5.620 -0.060 (-1.06%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Acelyrin Inc < Previous 1 2 3 4 5 6 Next > ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease October 16, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 September 19, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive September 10, 2024 From ACELYRIN, INC. Via GlobeNewswire SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024 August 13, 2024 SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 May 15, 2024 SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 March 28, 2024 SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace ACELYRIN, INC. to Participate in Upcoming Investor Conferences August 22, 2024 From ACELYRIN, INC. Via GlobeNewswire Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday August 20, 2024 Via Benzinga Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep August 14, 2024 Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. Via Benzinga Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session August 14, 2024 Via Benzinga ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results August 13, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 August 06, 2024 From ACELYRIN, INC. Via GlobeNewswire Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 08, 2024 Via Benzinga ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 June 05, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 May 29, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm May 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones May 09, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Announces Leadership Transition May 09, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 April 29, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights March 28, 2024 From ACELYRIN, INC. Via GlobeNewswire Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million March 27, 2024 From Avalo Therapeutics Via GlobeNewswire Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients March 20, 2024 Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... Via Benzinga ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease March 20, 2024 From ACELYRIN, INC. Via GlobeNewswire Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study March 11, 2024 Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show... Via Benzinga ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis March 11, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients March 11, 2024 From ACELYRIN, INC. Via GlobeNewswire ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications February 15, 2024 From ACELYRIN, INC. Via GlobeNewswire Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline January 16, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 15, 2024 WHY: NEW YORK, NY - (NewMediaWire) - January 15, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... Via NewMediaWire Topics Lawsuit Exposures Financial Legal SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN January 14, 2024 WHY: NEW YORK, NY - (NewMediaWire) - January 14, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... Via NewMediaWire Topics Lawsuit Exposures Financial Legal < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
